Skip to content
OpenCapital
Get started

AYTU BioPharma, Inc. AYTU Q4 2024 earnings

Reported February 12, 2025 · After market close

Revenue$16.2MMiss by $1.4MDiluted EPS-$0.28In line
Revenue estimate$17.6M
EPS estimate-$0.28

Next report

Sep 22, 2026 (in 2 months)
Revenue estimate$17.2M
EPS estimate-$0.22

Versus estimates

Revenue

Q1 2026$12.4MBeat by $358.3KQ4 2025$15.2MBeat by $3.0MQ3 2025$13.9MBeat by $1.3MQ2 2025$15.1MMiss by $2.8MQ1 2025$18.5MMiss by $380.5K
Q4 2024$16.2MMiss by $1.4M

Diluted EPS

Q1 2026-$0.53Miss by $0.22Q4 2025-$1.05Miss by $0.79Q3 2025-$0.08Miss by $0.02Q2 2025-$0.26Miss by $0.24Q1 2025$0.20Beat by $0.37
Q4 2024-$0.28In line

Ask the moment AYTU BioPharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did AYTU BioPharma, Inc. report Q4 2024 earnings?
AYTU BioPharma, Inc. (AYTU) reported Q4 2024 earnings on February 12, 2025 after market close.
What were AYTU BioPharma, Inc.'s Q4 2024 revenue and EPS?
AYTU BioPharma, Inc. reported revenue of $16.2M and diluted EPS of $-0.28 for Q4 2024.
Did AYTU BioPharma, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $17.6M by $1.4M. EPS beat the consensus estimate of $-0.28 by $0.00.
Where can I find AYTU BioPharma, Inc.'s Q4 2024 SEC filings?
You can read the 10-Q periodic report (0001437749-25-003568) directly on SEC EDGAR. The filing index links above go to sec.gov.